Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men

Radical prostatectomy (RP) is a primary treatment option for men with intermediate- and high-risk prostate cancer. Although many are effectively cured with local therapy alone, these men are by definition at higher risk of adverse pathologic features. It has been shown previously that genomic data can be used to predict tumor aggressiveness. Our objective was to evaluate genomic data and it's relationship to pathological stage and grade in a cohort of men that received no treatment other than radical prostatectomy surgery. Retrospective case-cohort design for 260 men who underwent RP between 1992 and 2010 at intermediate or high risk and received no additional treatment until the time of metastasis. Participants met the following criteria: (1) Cancer of the Prostate Risk Assessment postsurgical (CAPRA-S) score 3; (2) pathologic Gleason score 7; and (3) post-RP prostate-specific antigen nadir <0.2 ng/ml.

根治性前列腺切除术（radical prostatectomy, RP）是针对中高危前列腺癌男性患者的首选治疗方案。尽管不少患者仅通过该局部治疗即可获得有效治愈，但此类患者本身被归类为具有更高不良病理特征风险的人群。既往已有研究证实，基因组数据可用于预测肿瘤侵袭性。本研究旨在评估仅接受根治性前列腺切除术的男性队列中，基因组数据及其与病理分期和病理分级的关联。本研究采用回顾性病例队列设计，纳入260例1992年至2010年间接受根治性前列腺切除术的中高危前列腺癌患者，且在发生转移前未接受任何额外治疗。入组患者需满足以下标准：（1）术后前列腺癌风险评估（Cancer of the Prostate Risk Assessment postsurgical, CAPRA-S）评分=3；（2）术后病理格里森评分为7分；（3）根治性前列腺切除术后前列腺特异性抗原低谷值<0.2 ng/ml。